🚀 VC round data is live in beta, check it out!
Annexin Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Annexin Pharmaceuticals and similar public comparables like CalciMedica, Pure Biologics, Alzinova, Vivesto and more.
Annexin Pharmaceuticals Overview
About Annexin Pharmaceuticals
Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.
Founded
2014
HQ
Employees
5
Website
Sectors
Financials (LTM)
EV
$6M
Annexin Pharmaceuticals Financials
Annexin Pharmaceuticals reported last 12-month revenue of $2M and negative EBITDA of ($2M).
In the same LTM period, Annexin Pharmaceuticals generated ($2M) in EBITDA losses and had net loss of ($2M).
Revenue (LTM)
Annexin Pharmaceuticals P&L
In the most recent fiscal year, Annexin Pharmaceuticals reported revenue of — and EBITDA of ($4M).
Annexin Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | — | XXX | XXX | XXX |
| EBITDA | ($2M) | XXX | ($4M) | XXX | XXX | XXX |
| EBITDA Margin | (109%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (109%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($2M) | XXX | ($4M) | XXX | XXX | XXX |
| Net Margin | (108%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Annexin Pharmaceuticals Stock Performance
Annexin Pharmaceuticals has current market cap of $10M, and enterprise value of $6M.
Market Cap Evolution
Annexin Pharmaceuticals' stock price is $1.43.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6M | $10M | -14.6% | XXX | XXX | XXX | $-0.56 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAnnexin Pharmaceuticals Valuation Multiples
Annexin Pharmaceuticals trades at 2.8x EV/Revenue multiple, and (2.5x) EV/EBITDA.
EV / Revenue (LTM)
Annexin Pharmaceuticals Financial Valuation Multiples
As of April 10, 2026, Annexin Pharmaceuticals has market cap of $10M and EV of $6M.
Equity research analysts estimate Annexin Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Annexin Pharmaceuticals has a P/E ratio of (4.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10M | XXX | $10M | XXX | XXX | XXX |
| EV (current) | $6M | XXX | $6M | XXX | XXX | XXX |
| EV/Revenue | 2.8x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (2.5x) | XXX | (1.5x) | XXX | XXX | XXX |
| EV/EBIT | (2.5x) | XXX | (1.6x) | XXX | XXX | XXX |
| P/E | (4.2x) | XXX | (2.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Annexin Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Annexin Pharmaceuticals Margins & Growth Rates
Annexin Pharmaceuticals' revenue in the last 12 month grew by 165%.
Annexin Pharmaceuticals' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.8M for the same period.
Annexin Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 165% | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | (109%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | (93%) | XXX | (153%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Annexin Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| CalciMedica | XXX | XXX | XXX | XXX | XXX | XXX |
| Pure Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Alzinova | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivesto | XXX | XXX | XXX | XXX | XXX | XXX |
| Coegin Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Annexin Pharmaceuticals M&A Activity
Annexin Pharmaceuticals acquired XXX companies to date.
Last acquisition by Annexin Pharmaceuticals was on XXXXXXXX, XXXXX. Annexin Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Annexin Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAnnexin Pharmaceuticals Investment Activity
Annexin Pharmaceuticals invested in XXX companies to date.
Annexin Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Annexin Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Annexin Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Annexin Pharmaceuticals
| When was Annexin Pharmaceuticals founded? | Annexin Pharmaceuticals was founded in 2014. |
| Where is Annexin Pharmaceuticals headquartered? | Annexin Pharmaceuticals is headquartered in Sweden. |
| How many employees does Annexin Pharmaceuticals have? | As of today, Annexin Pharmaceuticals has over 5 employees. |
| Is Annexin Pharmaceuticals publicly listed? | Yes, Annexin Pharmaceuticals is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Annexin Pharmaceuticals? | Annexin Pharmaceuticals trades under ANNX ticker. |
| When did Annexin Pharmaceuticals go public? | Annexin Pharmaceuticals went public in 2017. |
| Who are competitors of Annexin Pharmaceuticals? | Annexin Pharmaceuticals main competitors are CalciMedica, Pure Biologics, Alzinova, Vivesto. |
| What is the current market cap of Annexin Pharmaceuticals? | Annexin Pharmaceuticals' current market cap is $10M. |
| What is the current revenue of Annexin Pharmaceuticals? | Annexin Pharmaceuticals' last 12 months revenue is $2M. |
| What is the current revenue growth of Annexin Pharmaceuticals? | Annexin Pharmaceuticals revenue growth (NTM/LTM) is 165%. |
| What is the current EV/Revenue multiple of Annexin Pharmaceuticals? | Current revenue multiple of Annexin Pharmaceuticals is 2.8x. |
| Is Annexin Pharmaceuticals profitable? | No, Annexin Pharmaceuticals is not profitable. |
| What is the current EBITDA of Annexin Pharmaceuticals? | Annexin Pharmaceuticals has negative EBITDA and is not profitable. |
| What is Annexin Pharmaceuticals' EBITDA margin? | Annexin Pharmaceuticals' last 12 months EBITDA margin is (109%). |
| What is the current EV/EBITDA multiple of Annexin Pharmaceuticals? | Current EBITDA multiple of Annexin Pharmaceuticals is (2.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.